These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 15993989)

  • 1. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
    Woo PC; Lau SK; Tsoi HW; Chen ZW; Wong BH; Zhang L; Chan JK; Wong LP; He W; Ma C; Chan KH; Ho DD; Yuen KY
    Vaccine; 2005 Oct; 23(42):4959-68. PubMed ID: 15993989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An oral mucosal DNA vaccine for SARS coronavirus infections.
    Yuen KY; Woo PC; Lau SK
    Hong Kong Med J; 2009 Feb; 15 Suppl 2():41-2. PubMed ID: 19258634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
    Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H
    Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
    Faber M; Lamirande EW; Roberts A; Rice AB; Koprowski H; Dietzschold B; Schnell MJ
    J Gen Virol; 2005 May; 86(Pt 5):1435-1440. PubMed ID: 15831955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.
    Wang X; Xu W; Tong D; Ni J; Gao H; Wang Y; Chu Y; Li P; Yang X; Xiong S
    Immunol Lett; 2008 Aug; 119(1-2):71-7. PubMed ID: 18533276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS.
    Callendret B; Lorin V; Charneau P; Marianneau P; Contamin H; Betton JM; van der Werf S; Escriou N
    Virology; 2007 Jul; 363(2):288-302. PubMed ID: 17331558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Potent neutralization antibody elicited in mice by SARS-associated coronavirus spike protein S1 domain].
    Zhang Y; Yang F; Li YH; Li WH; Tu XM; Wei Q; Zhu H; Liu L; Wang H; Qin C; Yuan GY; He W; Wang SH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):258-60. PubMed ID: 15640862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses.
    Huang J; Cao Y; Du J; Bu X; Ma R; Wu C
    Vaccine; 2007 Sep; 25(39-40):6981-91. PubMed ID: 17709158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
    Du L; Zhao G; Chan CC; Sun S; Chen M; Liu Z; Guo H; He Y; Zhou Y; Zheng BJ; Jiang S
    Virology; 2009 Oct; 393(1):144-50. PubMed ID: 19683779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus.
    Ba L; Yi CE; Zhang L; Ho DD; Chen Z
    Appl Microbiol Biotechnol; 2007 Oct; 76(5):1131-6. PubMed ID: 17581748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant Salmonella enterica serovar Typhimurium vaccine strain for immunization against infection with human-derived enterotoxigenic Escherichia coli strains.
    Lásaro MO; Luiz WB; Sbrogio-Almeida ME; Nishimura LS; Guth BE; Ferreira LC
    Infect Immun; 2004 Nov; 72(11):6480-91. PubMed ID: 15501779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
    Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
    Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
    He Y; Li J; Heck S; Lustigman S; Jiang S
    J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.
    Li J; Ulitzky L; Silberstein E; Taylor DR; Viscidi R
    Viral Immunol; 2013 Apr; 26(2):126-32. PubMed ID: 23573979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies.
    Kuate S; Cinatl J; Doerr HW; Uberla K
    Virology; 2007 May; 362(1):26-37. PubMed ID: 17258782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
    Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
    J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: secreted sq protein induces robust neutralization antibody in mice.
    Yan K; Tan W; Wang H; Wang Y; Zhang X; Li Y; Ruan L
    Viral Immunol; 2009 Feb; 22(1):57-66. PubMed ID: 19210229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of mice with a DNA vaccine based on severe acute respiratory syndrome coronavirus spike protein fragment 1.
    Zhao B; Jin NY; Wang RL; Zhang LS; Zhang YJ
    Viral Immunol; 2006; 19(3):518-24. PubMed ID: 16987069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.